Elite in Hemophilia B

Michiel J. Coppens

Amsterdam UMC Location AMC
Amsterdam, NH, NL 
Clinical Trials:Currently Recruiting for 1 Trial
Elite in Hemophilia B
Amsterdam UMC Location AMC
Amsterdam, NH, NL 
OverviewLocationsClinical Research

Overview

Michiel Coppens practices in Amsterdam, Netherlands. Mr. Coppens is rated as an Elite expert by MediFind in the treatment of Hemophilia B. His top areas of expertise are Hemophilia A, Blood Clots, Hemophilia B, and Venous Thromboembolism (VTE).

His clinical research consists of co-authoring 153 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 16 articles and participated in 1 clinical trial in the study of Hemophilia B.

Gender
Male

Locations

Amsterdam UMC Location AMC
Amsterdam, NH, Netherlands
Other Locations
Noord, NB, Netherlands

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Statins for Venous Event Reduction in Patients With Venous Thromboembolism
Statins for Venous Event Reduction in Patients With Venous Thromboembolism
Enrollment Status: Recruiting
Publish Date: June 27, 2025
Intervention Type: Drug
Study Drug: Rosuvastatin Calcium
Study Phase: Phase 3
Phase III, Open-label, Single-dose, Multi-center, Multinational Trial Investigating a Serotype 5 Adeno-associated Viral Vector Containing the Padua Variant of a Codon-optimized Human Factor IX Gene (AAV5-hFIXco-Padua, AMT-061) Administered to Adult Subjects With Severe or Moderately Severe Hemophilia B
Phase III, Open-label, Single-dose, Multi-center, Multinational Trial Investigating a Serotype 5 Adeno-associated Viral Vector Containing the Padua Variant of a Codon-optimized Human Factor IX Gene (AAV5-hFIXco-Padua, AMT-061) Administered to Adult Subjects With Severe or Moderately Severe Hemophilia B
Enrollment Status: Completed
Publish Date: May 04, 2025
Intervention Type: Genetic, Biological
Study Drug: AMT-061 Adeno-Associated Virus Padua Variant FIX Vaccine
Study Phase: Phase 3
View 1 Less Clinical Trial

153 Total Publications

Improving outcome in SubaraChnoid HEMorrhage wIth nAdroparin (ISCHEMIA): a prospective randomised controlled trial protocol.
Improving outcome in SubaraChnoid HEMorrhage wIth nAdroparin (ISCHEMIA): a prospective randomised controlled trial protocol.
Journal: BMJ open
Published: August 28, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Coppens's expertise for a condition
ConditionClose
View All 19 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile